Dongkuk Pharmaceutical announced that it participated in CPHI Worldwide 2025, the global pharmaceutical and biotech exhibition held in Frankfurt, Germany, from October 28 to 30.
CPHI Worldwide, which rotates among major European cities each year, drew more than 62,000 industry professionals and some 2,400 companies from over 160 countries this year. Dongkuk operated a dedicated booth to promote its microsphere-based long‑acting injectable (depot) products, Lorelin Depot and Octrelin Lar, emphasizing their technical strengths and competitive advantages.
The company also showcased Uresco tablets (dutasteride + tadalafil), an improved drug candidate for benign prostatic hyperplasia (BPH), highlighting Phase 3 clinical results that demonstrate strong efficacy and a favorable safety profile. According to Dongkuk, the Uresco program generated particularly active interest from global buyers.
During the event, Dongkuk’s booth hosted more than 300 meetings with existing and prospective partners, with intensive consultations focused on Uresco among other products. A company representative said global pharmaceutical firms showed significant interest in Dongkuk’s microsphere technology and product portfolio, and that the company used the opportunity to solidify partnerships and advance overseas market expansion plans.
Dongkuk Pharmaceutical has participated in CPHI Worldwide with a dedicated booth for four consecutive years since 2022.
